Biogen at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Biogen takes part in 2 sessions at CTAD 2026 in Boston. Its program covers new findings from the phase 2 CELIA study of diranersen in early Alzheimer's disease. Its work also maps US real-world patterns of amyloid testing and the start of anti-amyloid therapy.
| Organization | CTAD 2026 Attendance |
|---|---|
Biogen Cambridge, Massachusetts | ◆Platinum Sponsor |
Neuroscience drugmaker that co-developed lecanemab (Leqembi) with Eisai and develops tau-targeting therapies, including an antisense drug. | Talk Tue Nov 17 4:45pm–5:25pm |
Instantly find 20 buyers from Biogen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction